Dendrite Announces Management Change.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Nov. 20, 2002

Dendrite International, Inc. (NASDAQ: DRTE) today announced that Luke M. Beshar will be resigning as Senior Vice President and Chief Financial Officer in order to pursue interests outside the company, and that Kathleen Donovan, the company's Vice President and Treasurer, will be assuming the role of Acting Chief Financial Officer.

Ms. Donovan has been with Dendrite since 1997 and previously served as Chief Financial Officer, Dendrite Americas; Vice President and Corporate Controller; and Vice President, Planning and Analysis.

"We appreciate Luke's contributions during his tenure and wish him well in his future endeavors," stated John Bailye, Dendrite Chairman and Chief Executive Officer. "At the same time, Dendrite is most fortunate to have such a talented and experienced executive in Kathy Donovan to assume this role. Kathy has been a key member of our senior financial team for the past five years in a series of important positions, which well prepares her for this interim role."

About Dendrite

Dendrite enables pharmaceutical companies to have more of their drugs prescribed for improved patient health through the strategic optimization of their sales and marketing channels and clinical resources. Pharmaceutical sales representatives and their managers from over 150 companies, including 19 of the top 20 pharmaceutical companies, and 57 countries use Dendrite's sales channel management products and services. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products, our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; changes in demand for our products and services attributable to business and economic pressures on our major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; events that may affect the U.S. and world economies; retention of key senior managers; our ability to manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.